BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12M Series A Funding

  May 20, 2025

   · 

  5 min read
• Press Releases

  Apreo Health® Announces Presentation of Clinical Data from the BREATHE 1&2 Trials at ATS 2025 and Publication of Six-Month Data in American Journal of Respiratory and Critical Care Medicine

  May 20, 2025

   · 

  4 min read
• Press Releases

  Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

  May 20, 2025

   · 

  7 min read
• Press Releases

  Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations

  May 20, 2025

   · 

  8 min read
• Press Releases

  Pfizer Enters into Exclusive Licensing Agreement with 3SBio

  May 20, 2025

   · 

  7 min read
• Press Releases

  RevolKa Ltd. Secures 210 million JPY (US$1.4 million) Series A Extension Funding to Advance Therapeutic Programs

  May 20, 2025

   · 

  4 min read
• Press Releases

  Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

  May 20, 2025

   · 

  12 min read
• Press Releases

  Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

  May 20, 2025

   · 

  3 min read
• Press Releases

  Shift Bioscience Appoints Lord David Prior and Sir Tony Kouzarides to Support Long-Term Strategy for Cell Rejuvenation Therapeutics

  May 20, 2025

   · 

  4 min read
• Press Releases

  Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC

  May 20, 2025

   · 

  4 min read